1cP-AL-LAD

1cP-AL-LAD
Clinical data
Routes of
administration		Oral[1]
Drug classSerotonergic psychedelic; Hallucinogen
Pharmacokinetic data
Duration of action7–10 hours[1]
Identifiers
  • (6aR,9R)-4-(cyclopropanecarbonyl)-N,N-diethyl-7-prop-2-enyl-6,6a,8,9-tetrahydroindolo[4,3-fg]quinoline-9-carboxamide
PubChem CID
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC26H31N3O2
Molar mass417.553 g·mol−1
3D model (JSmol)
  • CCN(CC)C(=O)[C@@H]1C=C2[C@@H](Cc3cn(C(=O)C4CC4)c4cccc2c34)N(C1)CC=C
  • InChI=1S/C26H31N3O2/c1-4-12-28-15-19(25(30)27(5-2)6-3)13-21-20-8-7-9-22-24(20)18(14-23(21)28)16-29(22)26(31)17-10-11-17/h4,7-9,13,16-17,19,23H,1,5-6,10-12,14-15H2,2-3H3/t19-,23-/m1/s1
  • Key:VSABTUDYQCMWKE-AUSIDOKSSA-N

1cP-AL-LAD is a psychedelic drug of the lysergamide family related to lysergic acid diethylamide (LSD).[2][3][1][4] It is thought to act as prodrug of AL-LAD.[3][1][4] The drug has been encountered as a novel designer drug.[1][4]

Use and effects

See also: AL-LAD § Use and effects

The dose of 1cP-AL-LAD ranges from 20 to 350 μg orally, with an average dose being 100 to 225 μg.[4] Its duration is said to be 7 to 10 hours.[4] The drug is said to produce psychedelic effects that are weaker and shorter-lasting than those of LSD.[4]

Interactions

See also: Psychedelic drug § Interactions, and Trip killer § Serotonergic psychedelic antidotes

Chemistry

Analogues

Related compounds include 1cP-LSD, 1D-LSD, 1P-AL-LAD, and 1T-AL-LAD, among others.

History

1cP-AL-LAD has been sold as a designer drug.[2] It was first identified online in December 2020[1] and in France in June 2021.[4][2]

Society and culture

Canada

1cP-AL-LAD is not a controlled substance in Canada as of 2025.[5]

United States

1cP-AL-LAD is not an explicitly controlled substance in the United States.[6] However, it could be considered a controlled substance under the Federal Analogue Act if intended for human consumption.

See also

References

  1. ^ a b c d e f "1cP-AL-LAD". АИПСИН (in Russian). Retrieved 1 January 2026.
  2. ^ a b c Morais J, Evans-Brown M, Gallegos A, Christie R, Jorge R, Planchuelo G, et al. (2022-09-01). "New psychoactive substances: 25 years of early warning and response in Europe. An update from the EU Early Warning System". Toxicologie Analytique et Clinique. 30th meeting of SFTA- 59th meeting of TIAFT - September 2022. 34 (3, Supplement): S29–S30. Bibcode:2022ToxAC..34S..29M. doi:10.1016/j.toxac.2022.06.022. ISSN 2352-0078.
  3. ^ a b Kavanagh PV, Westphal F, Pulver B, Schwelm HM, Stratford A, Auwärter V, et al. (March 2023). "Analytical profile of the lysergamide 1cP-AL-LAD and detection of impurities". Drug Test Anal. 15 (3): 277–291. doi:10.1002/dta.3397. PMID 36321499.
  4. ^ a b c d e f g "1cP-AL-LAD". АИПСИН (in Russian). Retrieved 1 January 2026.
  5. ^ "Controlled Drugs and Substances Act". Department of Justice Canada. Retrieved 19 January 2026.
  6. ^ Orange Book: List of Controlled Substances and Regulated Chemicals (January 2026) (PDF), United States: U.S. Department of Justice: Drug Enforcement Administration (DEA): Diversion Control Division, January 2026
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.